Robotic Chemistry Speeds Discovery of Metal-Based Antibiotic Candidates

Robotic chemistry has created a fresh class of metal-based antibiotic candidates at a pace previously unattainable, revealing compounds that destroy dangerous bacteria without harming human cells.

The outcome changes expectations for how rapidly new antibiotics can be identified at a time when routine healthcare increasingly relies on medicines that no longer work.

When antibiotics stop working

In hospitals, infections that were once straightforward to cure are lingering as bacteria evolve more rapidly than new replacement drugs can arrive.

That divide began to close when Angelo Frei and his University of York colleagues recorded hundreds of previously unexamined metal compounds and detected antibacterial effects overlooked by conventional drug libraries.

Several of these compounds eradicated hard-to-treat bacteria while largely sparing human cells, an unusual pairing in early-stage antibiotic discovery.

The research shows that speed, rather than a shortage of chemistry alone, is a key limitation in the hunt for new antibiotics. That change in emphasis underlines the importance of alternative chemical approaches.

Why metals deserve attention

Most antibiotics are derived from carbon-based molecules, many of which share forms that bacteria can learn to resist.

Metal complexes - metal atoms secured by surrounding molecules - create more robust three-dimensional structures with different points of contact.

This shape may allow a compound to attach to bacterial proteins or membranes in unfamiliar ways, potentially evading established resistance mechanisms.

Metals also create safety concerns, meaning every promising hit must demonstrate that it damages microbes more than human cells.

Robots build chemical variety

Rather than producing candidates one by one, the laboratory automated synthesis to carry out dozens of reactions in parallel.

The 2025 research team reported producing more than 700 new metal compounds in less than one week.

Using click chemistry - rapid reactions that link two molecular components - the team efficiently attached small molecules to several metals.

Automation reduced months of manual work to days, although rigorous checks were still needed to prevent misleading results.

Testing without wasting time

Following synthesis, the scientists treated bacteria and human cells with each crude mixture, seeking strong bacterial killing with minimal damage.

This direct-to-biology method assesses reaction mixtures before purification, allowing promising compounds to progress more quickly.

“By combining smart ‘click’ chemistry with automation, we have demonstrated that we can explore vast, untapped areas of chemical space at unprecedented speed,” said Dr. Frei.

The rapid screens led the team to choose six lead candidates, which were then remade and purified to verify their effects.

A standout metal compound

An iridium-based compound stood out as the strongest antibiotic candidate, preventing Staphylococcus aureus from growing in laboratory tests.

It was also effective against strains related to methicillin-resistant Staphylococcus aureus, which can resist many standard medicines.

Researchers found a high therapeutic index - the difference between useful and harmful doses - because human cells remained relatively healthy.

Nevertheless, any safe medicine would require animal studies and detailed dosing research, as metals can act differently inside the body.

Breaking into tougher bacteria

Certain dangerous bacteria have a second external barrier that prevents many antibiotics from reaching their internal targets.

In the 2025 study, the metal compounds had little effect on Escherichia coli, a common gut bacterium protected by an additional outer membrane.

Their activity increased when researchers added polymyxin B nonapeptide, a fragment that relaxes the outer membrane and helps drugs enter more readily.

The finding identifies a clear next stage: redesigning these complexes so that they can cross this barrier independently.

How metals trip bacteria

Various metal designs can attack bacteria in multiple ways, an important feature when single-target drugs cease to work.

A metal centre can alter its charge and bind essential bacterial proteins, potentially halting processes required for growth.

The surrounding molecules also determine how a compound enters cells and where it remains inside them, influencing both its potency and safety.

Since bacteria evolve rapidly, researchers must still monitor for resistance that may emerge if a metal drug is used widely.

Testing metal toxicity

Metal medicines have long been associated with damage to healthy tissue, so researchers frequently encounter scepticism before testing begins.

A 2020 analysis showed that many metal complexes killed bacteria in screens without being more toxic than organic compounds.

The York team applied its own safety filters, testing every active compound against human cells and subsequently against red blood cells.

These early screens establish only a baseline, as real bodies process metals differently after they enter the bloodstream.

Building a faster pipeline

Global health agencies caution that antimicrobial resistance - when germs survive drugs intended to kill them - is already weakening everyday medical care.

The World Health Organization estimates that bacterial resistance was directly linked to 1.27 million deaths worldwide in 2019.

“We aren’t just looking for one drug; we are proving a methodology that can help us find the ‘needle in the haystack’ much faster,” said Frei.

If robotic chemistry continues to generate safe candidates, it could also enable industry to reconsider antibiotics previously regarded as too slow to develop.

A new pace for antibiotics

Combined, robotics and metal chemistry have provided scientists with a quicker means of finding bacteria-killing compounds while monitoring potential harm.

The research still requires more extensive testing, including animal studies and careful design for bacteria that are difficult to enter, before patients can benefit.

Image credit: Angelo Frei